+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Multi-Omics Technology in Human Health and Diseases. Genomics, Epigenomics, Transcriptomics, Proteomics, Metabolomics, Radiomics, Multi-omic

  • Book

  • March 2025
  • Elsevier Science and Technology
  • ID: 5850236
Multi-Omics Technology in Human Health and Diseases: Genomics, Epigenomics, Transcriptomics, Proteomics, Metabolomics, Radiomics, Multi-omic provides a way forward in understanding complete disease etiology and prognosis. This unique book gives a comprehensive understanding of multi-omics technology and its applications in understanding complex human health and disease, and not only introduces the technology, but also its use for biomarker identification, drug discovery, and disease prognostication. This is the first resource on currently utilized multiomics technology for big data interpretation, and is thus perfect for researchers, academia, students, and an industrial audience. As a comprehensive understanding of human health and diseases, particularly cancer, requires knowledge of molecular biomarkers at a multi-omics level, including genome, epigenome, transcriptome, proteome, and metabolome, which is meagerly available or highly lacking among the students and scientific researchers, this book checks all the right boxes.

Table of Contents

1. Introduction to Multi-Omics Technology
2. Multi-Omics data integration tools and approaches
3. Navigating the Multifaceted Landscape of Omics
4. Multi-omics in Cancer Research
5. Multi-omics for Disease subtyping and classification
6. Multi-Omics and Biomarker Discoveries in Alzheimer’s Disease
7. Multi-Omics and Drug Development
8. Multi-Omics Technology and Cancers
9. Multi-Omics Data for Machine Learning Algorithms
10. Challenges with Multi-Omics Data Integration
11. Multi-omics Technology and Cardiovascular Diseases

Authors

Muzafar A. Macha Assistant Professor and Ramalingaswami Fellow Head of Department Watson-Crick Center for Molecular Medicine, Islamic University of Science and Technology (IUST), Awantipora, Jammu & Kashmir, Awantipora, India. Dr. Macha is working as an Assistant Professor & Ramalingaswami Fellow in the Watson-Crick Center for Molecular Medicine, Islamic University of Science and Technology (IUST, India. In 2011 he joined the Department of Biochemistry and Molecular Biology (BMB), University of Nebraska Medical center (UNMC), USA, as a postdoctoral fellow, where he developed an independent HNC Research group and worked on the identification of deregulated signaling pathways and novel therapeutic targets. He published his work in many peer-reviewed Journals, including Journals, National Cancer Institute, Oncogene, Carcinogenesis, Cancer Treatment Reviews, Advanced Drug Delivery Reviews, BBA-Molecular Basis of Disease, Oncotarget, EBioMedicine. Tariq A. Masoodi Research Scientist, Department of Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Centre, Saudi Arabia. Dr. Masoodi is presently working as Research Scientist in the Department of Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Centre, Saudi Arabia. He completed his Ph.D. in Bioinformatics with focus on novel biomarker prediction in Breast cancer using Next Generation Sequencing (NGS) technology. He was promoted as Scientist and established a full fledged Bioinformatics section with facilities for working on multi-omics next generation sequencing data including whole exome/genome sequencing, RNA sequencing (mRNA, miRNAs and lncRNAs), metabolome and proteomics. His work focuses on understanding cancer in a more comprehensive manner using multi-omics approach by studying it at genome, transcriptome, epigenome and proteome level.. He is an active reviewer for many peer-reviewed journals. Ajaz A. Bhat research scientist at Sidra Medicine, Qatar.. Dr. Bhat is currently working as a research scientist at Sidra Medicine, Qatar. He completed his Ph.D. from All India Institute of Medical Sciences, AIIMS, New Delhi, one of the premier medical institutes in India, focusing on vaccine immunology. After his Ph.D., he moved to Vanderbilt University Medical School (VUMS), Nashville, TN, USA, for a postdoctoral fellowship. During his eleven years of post-PhD training, he gained broad experience of the pathobiological importance of tight junction proteins (Claudins) in colorectal cancer and the role of bile acid-induced APE1/Ref1 in the pathogenesis of esophageal cancer. He is an active member of many Immunology and Cancer societies and is serving in the editorial board and review committee of many peer-reviewed journals.